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regimens produce encouraging long term survival, with a low
incidence of GvHD and low toxicity, especially in patients with
early disease. The addition of MEL or TBI reduces RRD, but
increases signiﬁcantly TRM and does not improve survival . Dis-
ease phase remains a major predictor of outcome.
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KEPIVANCE USE IN ALLOGENEIC STEM CELL TRANSPLANTATION
Bayer, R.-L.1, Kim, B.1, John, V.1, Devoe, C.1, Cannon, M.1,
Klocke, J.1, Gissinger, D.1 1North Shore University Hospital, Manhas-
set, NY.
Kepivance (palifermin) is a human keratinocyte growth factor
produced by recombinant DNA technology. Kepivance is indi-
cated to decrease the incidence and duration of severe oral mu-
cositis in patients with hematologic malignancies receiving myelo-
toxic therapy requiring hematopoiectic stem cell support. Graft vs.
host disease remains as one of the major obstacles in allogeneic
stem cell transplantation. The role inﬂammatory cytokines play in
GVHD is well known. It has been postulated that if mucositis can
be lessened , cytokine storm will be less and hopefully GVHD.
When looking at the allogeneic stem cell transplant patients during
2005 and 2006 at our institution a trend for a decrease in severity
of acute GVHD was noted in patients treated with Kepivance (60
mcg / kg). We reviewed 10 patients prior to the institution of
Kepivance and 10 after. Only 6 of 10 patients received all six doses
of the drug. 4 out of 10 received only 5 doses. In both groups 8/10
patients had reduced intensity transplants and 2/10 had fully abla-
tive transplants. Average length of stay was 40 days for those
patients who received the drug and 43 for those who did not.
There did not seem to be any major differances between the
incidence of oral and GI mucositis or in the use of narcotics and IV
antibiotics. 9 out of 10 patients who did not get Kepivance had
neutropenic fever and all 10 with Kepivance did. With respect to
GVHD 3/10 who did not get Kepivance developed acute GVHD
and 2/10 patients who received the drug develped acute GVHD. In
the non Kepivance group 2 patients had grade 3/4 GVHD, and one
had grade 2. In the Kepivance group 2 patients had grade 2
GVHD. In the kepivance group 5 patients completed all planned
methotrexate doses for GVHD prophylaxis, and 8 patients in the
non-kepivance group. This review suggests that Kepivance may
lessen the severity of acute GVHD, but not via the mechanism
described above.
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DIFFERENTIAL REQUIREMENT FOR NKG2D IN THE REJECTION OF
HAPLOMISMATCHED AND MHC-I DEFICIENT BONE MARROW
Benjamin, J.E.1, Lanier, L.L.1 1University of Californa, San Francisco,
San Francisco, CA.
Mouse Natural Killer (NK) cells mediate rejection of MHC-
mismatched or MHC-deﬁcient bone marrow allografts. Coun-
teracting activating and inhibitory signals regulate NK cell
activity. The ability of F1 mice to reject parental bone marrow
(BM) cells (hybrid resistance) has been attributed to the pres-
ence in the recipient of a subset of NK cells that lack inhibitory
receptors for the MHC class I antigens expressed by the donor
cells. Evidence supporting the “missing self” hypothesis of hy-
brid resistance was provided by demonstration that MHC
class-I deﬁcient donor BM is rejected by otherwise syngeneic
recipients. We have previously demonstrated a role for
NKG2D, an activating NK cell receptor, in rejection of Balb/c
(H-2d) parental BM by (Balb/c x C57Bl/6; H-2b/d) F1 (CB6F1)
recipient mice. NKG2D ligands are expressed on the regener-
ating myeloid BM cells in Balb/c and NOD mice but not
substantially on the regenerating C57Bl/6 BM cells. Moreover,
the rejection of Balb/c BM by CB6F1 recipients was blocked by
a neutralizing anti-NKG2D monoclonal antibody. The purpose
of this study was to determine whether NKG2D blockade was
sufﬁcient to prevent rejection of MHC-I deﬁcient BM. Beta-2
microglobulin deﬁcient (B2M-/-) Balb/c or NOD bone marrow
was transplanted into irradiated CB6F1 mice that had been
pretreated with neutralizing antibodies to NKG2D. In contrast
to results with wild-type Balb/c or NOD BM whose rejection
was prevented by anti-NKG2D, B2M-/- donor cells were re-
jected despite NKG2D blockade. Furthermore, syngeneic
MHC class I Balb/c recipients were able to reject B2M-/-
Balb/c donors despite NKG2D blockade. These results suggest
that rejection of MHC class I-bearing BM requires activation
via NKG2D, whereas MHC class I-deﬁcient BM elicit a sufﬁ-
ciently strong NK response that augmentation by NKG2D
signaling is not essential for the rejection. Therefore, the hybrid
resistance model in which MHC class I-bearing BM are used for
transplantation may better reﬂect the situation in human hema-
topoietic stem cell transplantation.
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DETERMINATION OF ALEMTUZUMAB DOSE FOR REDUCED INTENSITY
CONDITIONING IN ALLOGENEIC TRANSPLANTATION
Bigelow, C.L.1, Elkins, S.L.1, Herrin, V.E.1, Hardy, C.L.1, Files, J.C.1
1University of Mississippi Medical Center, Jackson, MS.
From June, 2002, to August, 2006, our institution utilized
reduced intensity conditioning (RIC) regimens for 40 adult
at-risk older patients or those with comorbid conditions. Ma-
lignancies included multiple myeloma, AML, CML, NHL,
MDS, CLL and one renal cell carcinoma. Thirteen (32%) were
in CR at time of transplant while 27 (68%) had relapsed or
refractory disease. Median age was 50 years (range 24-66) and
median follow-up was eight months (1-36 months). Nine pa-
tients were single antigen or allele mismatches at either A, B or
DR. The other 31 patients were 6/6 or better antigen matches
at A, B and DR. Three RIC regimens were used: ﬂudarabine 30
mg/m2 x 5 days and melphalan 140 mg/m2 x 1 day in all groups,
and Alemtuzumab 20 mg/d x 5 days (protocol 1), x 3 days
(protocol 2), and x 2 days (protocol 3). Twenty-three patients
received MUD products and 17 received MRD products; cell
source was bone marrow (17), PBSC (19), cord blood (one) and
combination products (3). All patients received an adequate
CD34 cell dose or TNC dose (cord blood transplant). GVHD
prophylaxis was tacrolimus tapering after day 100 and myco-
phenolate mofetil tapering after day 30. Determination of the
optimal dose of Alemtuzumab was a goal of this study. All
patients except one achieved a WBC graft. Relapse or disease
progression occurred in only 37% of protocol 3, 40% of pro-
tocol 2 and 67% of protocol 1. Although Alemtuzumab dose was
given in a standard fashion not adjusted for body weight or
surface area it was found that lack of consideration of patient
size did not represent the intent of the given protocols. Weight-
based Alemtuzumab dose adjustment showed that a much
broader dose range than expected had occurred. Those receiv-
ing protocol 1 were in a dose range of 1.01-1.90 mg/kg; for
protocol 2 the range was 0.36-1.08 mg/kg; for protocol 3 the
range was 0.36-0.70, overlapping the previous group. The me-
dian dose of Alemtuzumab for the cohort was 0.68 mg/kg. A
clustering of acute GVHD grades I-II appeared below the
median dose at approximately 0.55 mg/kg; only one patient had
grade IV acute GVHD. In summary, formulation of a condi-
tioning protocol that balances engraftment and recurrence of
primary disease on the backdrop of a newly reconstituted im-
mune system is problematic. These data indicate that using the
patient’s body weight in the determination of an optimal Ale-
mtuzumab dose is a more reasonable approach to developing
and standardizing RIC protocols with this drug.
228
NONMYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
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